Amedica Corporation (NASDAQ:AMDA), a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, is pleased to announce all four submissions to the Orthopaedic Research Society (“ORS”) Annual Meeting were accepted for presentation occurringMarch 5-8, 2016 in Orlando, Florida.

“Our presentations will demonstrate the rationale for using our proprietary silicon nitride composition in a variety of medical applications within the $15 billion surgical spine, dental, hip and knee replacement markets,” said Dr. Sonny Bal, Chairman and CEO of Amedica Corporation. “This scientific data will convincingly demonstrate the serious limitations of other existing biomaterials, while highlighting the advantages of silicon nitride, even as we continue further testing on an improved second generation silicon nitride composition. I’m very proud of our continued innovation and robust science, which will be presented at this important orthopedic forum.”

Accepted submission titles and their authors include:

  • Metal Ions Contribute to the Material Instability of Zirconia Toughened Alumina – Giuseppe Pezzotti, Leonardo Puppulin, Marco Boffelli, Nobuhiko Sugano, Bryan J. McEntire (Presenter), and B. Sonny Bal
  • Differential Bacterial Expression on Silicon Nitride, PEEK, and Titanium Surfaces – Bryan J. McEntire (Presenter), Erin N. Jones, Darin Ray, Ryan M. Bock, B.Sonny Bal, and Giuseppe Pezzotti
  • Do Ceramic Femoral Heads Contribute to Polyethylene Oxidation? – Bryan J. McEntire (Presenter), Yuto Enomoto, Wenliang Zhu, Marco Boffelli, Elia Marin, B. Sonny Bal, and Giuseppe Pezzotti
  • Differential Effects of Hydrothermal Ageing on the Surface Fracture Toughness of Ceramics – Bryan J. McEntire (Presenter), Erin N. Jones, Darin Ray, Ryan M. Bock,B.Sonny Bal, and Giuseppe Pezzotti

The ORS annual meeting attracts attendees from all over the world—clinicians, surgeons, residents, veterinarians, basic scientists, and engineers who come together to present the latest innovative and cutting-edge musculoskeletal research. (Original Source)

Shares of Amedica are down 2.50% to $1.90 in pre-market trading. AMDA has a 1-year high of $13.20 and a 1-year low of $1.16. The stock’s 50-day moving average is $1.71 and its 200-day moving average is $4.54.

On the ratings front, Needham analyst Michael Matson reiterated a Buy rating on AMDA, with a price target of $15, in a report issued on November 13. The current price target represents a potential upside of 669.2% from where the stock is currently trading. According to, Matson has a total average return of -5.1%, a 39.5% success rate, and is ranked #3265 out of 3596 analysts.

Amedica Corp s a commercial-stage biomaterial company. It is engaged in using its silicon nitride technology platform to develop, manufacture & commercialize medical devices. Its products include valeo interbody fusion devices & facet fixation.